Even with all that, the company has more irons in the fire. Earlier this year it inked a nonexclusive licensing pact for its Ultragenyx HeLa manufacturing platform with Japanese pharma Daiichi Sankyo. It also licensed technology to drug giant Bayer for that company's work in developing drugs to treat hemophilia A.